Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis

2014156 citationsJournal Articlegold Open Access

Authors

Bone-marrow-MSCs are safe and may reduce inflammatory MRI parameters supporting their immunomodulatory properties. ClinicalTrials.gov NCT01228266.

Good health and well-being

Published in: PLoS ONE

Volume 9, Issue 12, pp. e113936-e113936

Field-Weighted Citation Impact: 9.50